Leemans et al., 2018 - Google Patents
Removal of the N-glycosylation sequon at position N116 located in p27 of the respiratory syncytial virus fusion protein elicits enhanced antibody responses after DNA …Leemans et al., 2018
View HTML- Document ID
- 11868817515420484813
- Author
- Leemans A
- Boeren M
- Van der Gucht W
- Pintelon I
- Roose K
- Schepens B
- Saelens X
- Bailey D
- Martinet W
- Caljon G
- Maes L
- Cos P
- Delputte P
- Publication year
- Publication venue
- Viruses
External Links
Snippet
Prevention of severe lower respiratory tract infections in infants caused by the human respiratory syncytial virus (hRSV) remains a major public health priority. Currently, the major focus of vaccine development relies on the RSV fusion (F) protein since it is the main target …
- 102000004965 antibodies 0 title abstract description 64
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halwe et al. | Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection | |
| Wu et al. | Structural biology of influenza hemagglutinin: An amaranthine adventure | |
| Leemans et al. | Removal of the N-glycosylation sequon at position N116 located in p27 of the respiratory syncytial virus fusion protein elicits enhanced antibody responses after DNA immunization | |
| Anderson et al. | Functional features of the respiratory syncytial virus G protein | |
| Donofrio et al. | A simplified SARS-CoV-2 pseudovirus neutralization assay | |
| Loes et al. | Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice | |
| Huang et al. | Next generation of computationally optimized broadly reactive HA vaccines elicited cross-reactive immune responses and provided protection against H1N1 virus infection | |
| Bergeron et al. | Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies | |
| Patel et al. | Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity | |
| Woelfl et al. | Novel toscana virus reverse genetics system establishes nss as an antagonist of type I interferon responses | |
| Rabaan et al. | Variants of SARS-CoV-2: Influences on the vaccines’ effectiveness and possible strategies to overcome their consequences | |
| Lainšček et al. | A nanoscaffolded spike-RBD vaccine provides protection against SARS-CoV-2 with minimal anti-scaffold response | |
| Chu et al. | Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 S glycoprotein, S1, or S2 domains | |
| Ha et al. | Mutation of respiratory syncytial virus G protein’s CX3C motif attenuates infection in cotton rats and primary human airway epithelial cells | |
| Zhang et al. | Genetically modified rabies virus vector-based rift valley fever virus vaccine is safe and induces efficacious immune responses in mice | |
| Cullen et al. | Comparison of immune responses to different versions of VLP associated stabilized RSV pre-fusion F protein | |
| Isaacs et al. | Combinatorial FG immunogens as Nipah and respiratory syncytial virus vaccine candidates | |
| Russell et al. | Sendai virus-vectored vaccines that express envelope glycoproteins of respiratory viruses | |
| Wilmschen et al. | RSV vaccine based on rhabdoviral vector protects after single immunization | |
| Grandi et al. | Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine | |
| Ma et al. | Immunization with a prefusion SARS-CoV-2 spike protein vaccine (RBMRNA-176) protects against viral challenge in mice and nonhuman primates | |
| Ha et al. | Two RSV platforms for G, F, or G+ F proteins VLPs | |
| Huang et al. | Single-domain antibodies as therapeutics for respiratory RNA virus infections | |
| Shimojima et al. | Neutralizing mAbs against SFTS virus Gn protein show strong therapeutic effects in an SFTS animal model | |
| Zhang et al. | Characterization of humoral responses induced by an H7N9 influenza virus-like particle vaccine in BALB/c mice |